Global /United States /Healthcare /Biotechnology /PRLD

Prelude Therapeutics Inc.

PRLD

• NASDAQ: PRLD • Delayed

4.27USD -2.7%

As of 13 June 2026, Prelude Therapeutics Inc. has a market cap of $429.36M USD, ranking #16194 globally and #2743 in the United States. It ranks #1458 in the Healthcare sector, and #281 in the Biotechnology industry.

Global Rank

16194

Country Rank

2743

Sector Rank

1458

Industry Rank

281

Key Stats

Market Cap

$429.36MUSD

Enterprise Value

$345.95MUSD

Revenue (TTM)

$12.14MUSD

EBITDA (TTM)

-$101.56MUSD

Net Income (TTM)

-$99.5MUSD

PS Ratio

35.5

PB Ratio

5.2

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Krishna Vaddi open_in_new

Employees

Founded

2016

IPO

25 Sep 2020

Website

preludetx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.7%	-1.6%	39%	115%	175%	46%	378%	-34%	-89%

News

PRLD Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	PRLD Prelude Therapeutics Inc Ordinary Shares ISIN: US74065P1012 Shares Out.: Shares Outstanding: 64.917M¹ Shares Float: 41.756M² TV: TradingView: NASDAQ: PRLD SA: Stock Analysis: NASDAQ: PRLD YF: Yahoo Finance: PRLD GF: Google Finance: NASDAQ: PRLD NQ: NASDAQ: PRLD BA: Barron's: PRLD MS: Morningstar: XNAS: PRLD	4.27 USD	TV: TradingView: NASDAQ: PRLD SA: Stock Analysis: NASDAQ: PRLD YF: Yahoo Finance: PRLD GF: Google Finance: NASDAQ: PRLD NQ: NASDAQ: PRLD BA: Barron's: PRLD MS: Morningstar: XNAS: PRLD

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Prelude Therapeutics Inc.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 42K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 37K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 6K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 6K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 6K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 4K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 11K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 10K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 10K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 10K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 6K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 6K%	-	Germany

chevron_leftBack